MML Investors Services LLC Has $13.86 Million Stock Position in Stryker Co. (NYSE:SYK)

MML Investors Services LLC boosted its holdings in shares of Stryker Co. (NYSE:SYK - Free Report) by 8.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 38,491 shares of the medical technology company's stock after acquiring an additional 3,099 shares during the quarter. MML Investors Services LLC's holdings in Stryker were worth $13,859,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Morse Asset Management Inc lifted its position in Stryker by 16.5% in the 3rd quarter. Morse Asset Management Inc now owns 1,410 shares of the medical technology company's stock worth $509,000 after buying an additional 200 shares in the last quarter. World Investment Advisors LLC raised its holdings in shares of Stryker by 126.1% during the third quarter. World Investment Advisors LLC now owns 8,142 shares of the medical technology company's stock worth $2,941,000 after acquiring an additional 4,541 shares in the last quarter. Arvest Bank Trust Division acquired a new stake in Stryker during the third quarter valued at $245,000. Wilmington Savings Fund Society FSB grew its stake in Stryker by 13.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 44,795 shares of the medical technology company's stock valued at $16,183,000 after purchasing an additional 5,361 shares in the last quarter. Finally, Tidal Investments LLC increased its position in Stryker by 13.9% in the 3rd quarter. Tidal Investments LLC now owns 17,478 shares of the medical technology company's stock worth $6,314,000 after purchasing an additional 2,139 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Stifel Nicolaus boosted their price target on Stryker from $400.00 to $440.00 and gave the company a "buy" rating in a research note on Wednesday, January 29th. Barclays increased their price target on shares of Stryker from $418.00 to $443.00 and gave the stock an "overweight" rating in a research note on Monday, February 10th. Royal Bank of Canada lifted their price objective on shares of Stryker from $425.00 to $435.00 and gave the company an "outperform" rating in a research note on Wednesday, January 29th. JMP Securities reissued a "market perform" rating on shares of Stryker in a research report on Tuesday, February 18th. Finally, The Goldman Sachs Group set a $422.00 price target on Stryker in a research note on Tuesday, March 4th. Five research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat, Stryker currently has a consensus rating of "Moderate Buy" and an average target price of $423.53.

Stryker Price Performance

Shares of SYK stock opened at $348.62 on Wednesday. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The company has a market capitalization of $133.06 billion, a P/E ratio of 44.93, a P/E/G ratio of 2.93 and a beta of 0.93. The stock has a 50 day moving average of $369.25 and a two-hundred day moving average of $373.06. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping analysts' consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the prior year, the company earned $3.46 EPS. As a group, equities analysts expect that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.96%. The ex-dividend date of this dividend is Monday, March 31st. Stryker's payout ratio is 43.30%.

Insider Activity

In other news, Director Allan C. Golston sold 2,458 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now owns 14,895 shares of the company's stock, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares of the company's stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.20% of the company's stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.